Drugs & Targets Kymab, Roche agree to evaluate KY1044, anti-PD-L1 immunotherapy in solid tumors June 29, 2018Vol.44 No.26
Drugs & Targets FDA grants orphan drug designation for CPI-613 for Burkitt lymphoma June 29, 2018Vol.44 No.26
Drugs & TargetsFree FDA to review BRACAnalysis CDx sPMA as companion diagnostic for Talazoparib June 22, 2018Vol.44 No.25
Drugs & TargetsFree China’s drug agency approves Opdivo for previously treated NSCLC June 22, 2018Vol.44 No.25
Drugs & TargetsFree Natera, Institut Jules Bordet to collaborate on neoadjuvant breast cancer assay June 22, 2018Vol.44 No.25
Drugs & Targets FDA approves Avastin in combination with chemotherapy for ovarian cancer June 15, 2018Vol.44 No.24
Drugs & Targets FDA approves Keytruda for previously treated patients with recurrent or metastatic cervical cancer whose tumors express PD-L1 June 15, 2018Vol.44 No.24
Drugs & Targets TESARO, Genentech to study Zejula with anti-PD-L1 agent, MEK inhibitor in ovarian cancer June 15, 2018Vol.44 No.24
Drugs & Targets FDA approves Venclexta with rituximab as a fixed duration treatment for CLL or SLL after one prior therapy June 15, 2018Vol.44 No.24
